Bruce Power has been given approval from the Canadian Nuclear Safety Commission to operate an on site hot cell facility which will spark the way for continued leadership for producing cancer fighting medical isotopes.
The CNSC’s approval will allow Bruce Power to use the facility to perform Target Carrier Removal, an important step in the production process for LU-177, a medical isotope used to treat prostate cancer and increasing number of targeted therapies in precision medicine.
Construction of the hot cell was done earlier this year through a collaboration involving Bruce Power, Kinectrics, Bird Construction and a team from across Bruce Power’s operations, engineering, licensing, radiation protection, safety and business development organizations.







